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Since their introduction in the 1970s, hydroxyethyl starches (HESs) have found widespread uses in peri-operative and critical care medicine. Perioperatively 
their administration has been associated with reduced fluid 
requirements, increased tissue oxygen tension, and bet-
ter hemodynamic stability. However, especially in the past 
decade, there has been an intensive debate concerning the 
safety of HES preparations. A number of studies in critically 
KEY POINTS
• Question: Does the administration of hydroxyethyl starch (HES) 130/0.4 increase the fre-
quency of postoperative kidney failure in a perioperative setting?
• Findings: In a large propensity score matched cohort with Ringer’s acetate as a comparator, 
the use of HES 130/0.4 was not related to postoperative kidney failure.
• Meaning: Perioperative therapy with HES 130/0.4 has no association to kidney failure, when 
administered in a mixed cohort of elective surgical patients.
BACKGROUND: Adverse effects of hydroxyethyl starches (HESs) have been verified in patients 
suffering from sepsis or kidney disease, but not in surgical patients at large. The investigation 
aimed to determine whether the use of HES 130/0.4 was associated with the incidence of 
acute postinterventional adverse events compared to Ringer’s acetate alone in a perioperative 
setting.
METHODS: This propensity score matched, controlled observational study was performed in a 
single-centre university hospital. The perioperative data of 9085 patients were analyzed. Group 
matching was based on 13 categories including demographic data, type of procedure, and 5 
preexisting comorbidities. Duration of procedure and intraoperative transfusion requirements 
were integrated in the matching process to reduce selection and indication bias. The primary 
outcome was incidence of postoperative kidney failure. Secondary outcomes were in-hospital 
mortality, fluid requirements, blood loss, hemodynamic stability, and the need for postoperative 
intensive care unit (ICU) treatment.
RESULTS: The administration of HES 130/0.4 was not associated with an increased frequency 
of postoperative kidney failure. In-hospital mortality (Ringer’s acetate: 2.58%; HES 130/0.4: 
2.68%) and the need for ICU care (Ringer’s acetate: 30.5%; HES 130/0.4: 34.3%) did not differ 
significantly between groups. Significant intergroup differences were observed for mean blood 
loss (Ringer’s acetate: 406 ± 821 mL; HES 130/0.4: 867 ± 1275 mL; P < .001) and median 
length of hospital stay (Ringer’s acetate: 10.5 (5/17) days; HES 130/0.4: 12.0 (8/19) days; 
P < .001).
CONCLUSIONS: An association between intraoperative HES therapy and postoperative kid-
ney failure was not observed in a mixed cohort of elective surgical patients. In addition, HES 
130/0.4 was not associated with an increased morbidity or the need for ICU therapy in this 
propensity score matched study.  (Anesth Analg 2018;126:1949–56)
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ill patients have suggested that the use of HES might have 
detrimental effects on kidney function in patients with 
severe sepsis and/or renal disease.1–3 Though the method-
ological quality and the results of these studies have been 
extensively discussed, there was sufficiently compelling 
evidence against using HES in intensive care medicine for 
the European Medicines Agency (EMA) to recommend 
revoking their approval (EMA, 640658) in June 2013.4
Though adverse effects of HES have been clearly veri-
fied in intensive care unit (ICU) patients, they have not been 
established in surgical patients at large.5–7 Thus, the limita-
tions concerning the perioperative use of HES have been 
partially revised by some national expert committees.8
While acute kidney injury occurs frequently in intensive 
care medicine, the incidence has been put at below 5% in 
patients scheduled for low- to medium-risk surgery.9 As 
a consequence, very large randomized controlled trials 
would be necessary to detect adverse effects of HESs on 
renal function in a routine perioperative setting, which, to 
date, have not been forthcoming. High-quality propensity 
score matching can mimic randomization to some extent 
and, when generated out of retrospective cohort analyses, 
is able to provide large numbers of patients.10 In addition, a 
propensity score matched cohort analysis can be controlled 
rather effectively with respect to patient population uni-
formity, confounders, and variables of interest.5–7 We con-
ducted a large-scale investigation of surgical patients who 
had received either Ringer’s acetate (RA) alone or in com-
bination with HES 130/0.4 (hydroxyethyl starch, molecular 
weight 130 kDa; degree of substitution 0.4, waxy maize-
based). Propensity score group matching was performed 
to adjust for known confounders and to reduce bias. We 
hypothesized that there would be an association between 
the use of HES 130/0.4 and postoperative kidney failure.
METHODS
Data Generation and Subject Selection
After approval by the Ethics Committee of the University 
of Munich, we accessed the software used to generate our 
department’s electronic anesthesia records (NarkoData, 
IMESO GmbH, Giessen, Germany). This software is based 
on a database collecting anesthesia-relevant periopera-
tive data for all patients undergoing anesthesia. Second, 
the hospital’s patient data management system (KAS, 
SAP Deutschland SE & Co. KG, Walldorf, Germany) was 
accessed. It captures administrative data such as length of 
hospital stay (LOSH) and some medical information such 
as patient’s comorbidities. Finally, the hospital’s laboratory 
database was used to retrieve perioperative laboratory val-
ues. Using these 3 databases, a set of parameters was gen-
erated which, on the one hand, enabled a propensity score 
matching process and, on the other hand, provided a set of 
defined outcome variables. Informed consent was waived 
because patient data were irreversibly anonymized before 
extraction (Clinical Trial Number: UE 102–14). This manu-
script adheres to the applicable Enhancing the QUAlity and 
Transparency Of health Research (EQUATOR) guidelines.
Data deriving from surgical procedures were analyzed 
to compare 2 groups of patients who either received RA 
alone (Jonosteril, Fresenius Kabi, Bad Homburg, Germany) 
(group RA) or a combination of RA with HES 130/0.4 
(Voluven, Fresenius Kabi, Bad Homburg, Germany) (group 
RA-HES). A similar comparison, which is demonstrated in 
Supplemental Digital Content 1, Appendix 1, http://links.
lww.com/AA/C194, was performed between RA and a 
20% albumin solution (Human-Albumin 20% Behring, CSL 
Behring GmbH, Marburg, Germany) (group RA-Alb).
To initiate this retrospective analysis, all adult patients 
undergoing surgical or diagnostical procedures requiring 
anesthesia during a 6-month period were evaluated. Part 1 
of this 6-month period took place from August 1, 2012 to 
October 31, 2012. Part 2 was from August 1, 2013 to October 
31, 2013, when HES 130/0.4 was not used at the authors’ 
institution due to the restrictions imposed by the EMA in 
June 2013.4 Thus, patients who had received HES 130/0.4 
derived solely from the 2012 period. Patients in group RA 
were enrolled in both periods. The temporal subdivision of 
data sampling was necessary to gather a sufficient number 
of patients for group RA who matched patients of group 
RA-HES in terms of comorbidities, as well as course and 
type of surgery. This could not be achieved exclusively in 
2012 when HES 130/0.4 was available. In patients who 
underwent more than 1 surgery, only the first procedure 
was included in the analysis and the observation period 
was finished at the time of the second procedure.
Second, patients undergoing diagnostic procedures and 
surgical procedures without a relevant risk of bleeding 
(for example ophthalmologic surgery) who had no indica-
tion for colloid use, as well as those with datasets lacking 
an exact procedure specification, were excluded from the 
analysis (Figure).11
Finally, from this cohort, 2 subgroups were established: 
Subgroup 1 consisted exclusively of patients undergoing 
major surgery, implicating a high risk of significant bleed-
ing. This subgroup was created from the whole cohort 
before any matching and its study groups (RA; RA-HES) 
were subsequently matched separately (Figure).
Subgroup 2 was built out of the whole cohort after pro-
pensity score matching and consisted of patients in whom 
the RIFLE criteria could be applied. The RIFLE criteria (an 
acronym indicating Risk of renal failure, Injury to the kid-
ney, Failure of kidney function, Loss of kidney function, and 
End-stage renal failure) are a diagnostic means to evaluate 
changes in postprocedural kidney function put forward by 
the Acute Dialysis Quality Initiative group in 2004.12 They 
are based on a calculated ratio of pre-and postprocedural 
creatinine values, among other parameters. The serum cre-
atinine cutoff values characterizing the RIFLE classes are 
given in Supplemental Digital Content 2, Table A2/1 in 
Appendix 2, http://links.lww.com/AA/C195.12–14
After propensity score matching, group-wise compari-
sons were performed according to the Figure. Our hypoth-
esis, statistical analysis plan, and primary and secondary 
outcomes were clearly defined before data interrogation.
The primary outcome was frequency of acute postopera-
tive kidney failure (pAKF). pAKF was defined as a patient 
needing any kind of postprocedural renal replacement ther-
apy (RRT) for the first time in his or her patient career.
Secondary outcome parameter was the in-hospital 
mortality after surgery. Patients who were discharged 
from the hospital were considered survivors and the 
mortality rates of patients transferred to other hospitals 
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were not evaluated. Further secondary outcomes were 
intraoperative fluid requirements (crystalloids and col-
loids), platelet, fresh frozen plasma requirements, mean 
blood loss, mean arterial pressure (MAP), and mean 
heart rate. LOSH and the necessity for ICU admission 
were also investigated. In subgroup 1, the same primary 
and secondary outcomes as for the whole cohort were 
evaluated.
In subgroup 2, the RIFLE criteria could be applied 
because both pre- and postoperative creatinine values 
were available (Figure).13 The post/preoperative creati-
nine ratios were calculated and regarded as a secondary 
outcome parameter. If more than 1 preoperative creatinine 
value was available, the latest preoperative value was 
used. If more than 1 postoperative value was known, 
the maximum creatinine value until the 90th postopera-
tive day was used. Because the duration of postoperative 
serum creatinine monitoring was not controlled, the RIFLE 
criteria of “Loss” and “End-stage renal disease” could not 
be applied.14
During the study, intraoperative fluid therapy was 
administered according to well-defined standard operat-
ing procedures (SOPs), which are given in Supplemental 
Digital Content 2, Table A2/2 in Appendix 2, http://links.
lww.com/AA/C195.15–18 The appropriate application of 
these SOPs by duty anesthetists was trained in repeated 
department-wide teaching sessions and was controlled by 
supervising senior physicians.
Figure. Flow chart of patient selec-
tion. HES indicates hydroxyethyl 
starch 130/0.4; RA, Ringer’s acetate; 
RIFLE, Risk of renal failure, Injury to 
the kidney, Failure of kidney function, 
Loss of kidney function, and End-
stage renal failure.
Copyright © 2018 International Anesthesia Research Society. Unauthorized reproduction of this article is prohibited.
1952   www.anesthesia-analgesia.org ANESTHESIA & ANALGESIA
HES 130/0.4 Is Not Associated With Kidney Failure
Statistical Analysis
For all data analyses, SPSS version 23 (IBM Corporation, 
Armonk, NY), Microsoft Excel 2016 (Microsoft 
Corporation, Redmond, WA), and the free software pack-
age “R,” version 3.3.1 including the “Matchit” and the 
“ROC” plugin, were used. The existence of a Gaussian 
distribution of data was evaluated using the Kolmogorov-
Smirnov test; to test for equal variances, the F test was 
applied. Skewed data are displayed as median ± inter-
quartile range, otherwise they are given as mean ± stan-
dardized deviation of the mean.
To account for potential confounders between study 
groups, each patient who was given both crystalloids and 
HES (group RA-HES) was matched to a control patient 
who was given only RA (group RA) across 13 different 
variables: gender, age, body mass index, physical status 
according to the American Society of Anaesthesiologists 
classification system, duration of surgery, type of surgical 
procedure, the number of packed red blood cells (PRBCs) 
transfused, maximal intraoperative noradrenaline require-
ments, and up to 5 preexisting comorbidities. Procedure 
type was classified according to the German OPS catalog 
version 2016, whereby codes were combined into 24 main 
categories.19 Comorbidities were classified according to 
International Classification of Diseases (ICD-10) catalog.20 
Comorbidities were combined into 17 main categories 
according to the Charlson comorbidity index using the algo-
rithms of Deyo and Quan (Supplemental Digital Content 
2, Table A2/3 in Appendix 2, http://links.lww.com/AA/
C195).21–23 Intraoperative PRBC transfusion and noradrena-
line requirements are known to directly influence pAKF.24 
Independently of this fact they merited inclusion into the 
matching process because alongside length of surgery, these 
parameters are important markers of the severity of the sur-
gical pathology and the complexity of the intraoperative 
course, which in our point of view may be a further impor-
tant “confounding factor.” On the other hand, intraopera-
tive blood loss was not included because duty anesthetists 
can only roughly estimate it. MAP is known to affect renal 
function, but it in turn is influenced by the nature of fluid 
therapy and was therefore interpreted as being an outcome 
parameter. To obtain the best matching results, ie, to com-
pare only patients who shared a maximum of similarities, 
the “nearest neighbor method” was applied and a strict 1:1 
ratio was maintained with regard to the 2 study groups. 
After matching, the Mann-Whitney U test was used for 
group comparisons when data were not normally distrib-
uted; otherwise a Student t test or Welch test was applied. 
Associations regarding categorical demographic and out-
come variables were assessed using Pearson χ2 test or Fisher 
exact test where necessary. Concerning the primary out-
come parameter, the odds ratio, its 95% confidence interval 
(CI), and the corresponding P value were calculated. P val-
ues were used as a measure of overall significance. For all 
comparisons, a value of P < .05 was considered significant.
RESULTS
Structure of Retrieved Data and Demographic 
Analysis
In total, the data of 9085 surgical patients were analyzed. 
During the matching process, the number of patients was 
reduced to 2168 for the whole cohort and 916 for sub-
group 1, to provide a maximum conformity between the 
study groups (Figure). Demographic data before and after 
matching are shown in Table  1. All patient demographic 
variables were well balanced after matching. Perioperative 
data contributing to matching are also demonstrated in 
Table  1. ASA classification and duration of surgery data 
were well balanced, whereas number of PRBCs transfused 
and maximum noradrenaline requirement still differed 
between groups. The distribution of surgical and diag-
nostic procedures is given in Table 2, showing that some 
significant differences between groups persisted despite 
matching. Nevertheless, the frequency of high-risk surgi-
cal procedures in group RA increased after matching. The 
fact that HES 130/0.4 was only administered in surgical 
procedures accompanied by a relevant blood loss led to 
a corresponding increase in high-risk surgeries in the RA 
group. As pointed out above, the frequency of 17 catego-
ries of comorbidities was also part of the matching pro-
cess. After matching, significant differences concerning 
this item could no longer be noticed between study groups 
(Supplemental Digital Content 2, Table A2/3 in Appendix 
2, http://links.lww.com/AA/C195; P > .05 for all group 
comparisons). Data concerning the quality of the match-
ing procedure are given in Supplemental Digital Content 
3, Tables A3/1–A3/8 and Figures A3/1–A3/4 in Appendix 
3, http://links.lww.com/AA/C196. Overall, a balance 
Table 1.   Demographic and Perioperative Data Before and After Matching
 
All Before Matching
Crystalloid Versus HES After Matching
 RA RA-HES
N (patients) 9085 1084 1084
Age (y) 56 (38/70) 65 (52/74) 65 (49/73)
BMI (kg) 25.5 (22.5/28.4) 25.8 (23.0/29.4) 25.9 (23.4/29.3)
Gender (M/F) (%) 49.0/51.0 47.9/52.1 48.1/51.9
ASA classification 2.0 (2.0/3.0) 3.0 (2.0/3.0) 3.0 (2.0/3.0)
Duration of surgery (min) 68 (34/128) 121 (58/219) 134 (71/204)
PRBC (mL) 32 ± 195 119 ± 386a 173 ± 529a
Maximum noradrenaline requirements during surgery (mg/h) 0.22 ± 0.40 0.52 ± 0.71b 0.65 ± 2.32b
Skewed data are given as median (25th/75th percentile), normally distributed data as mean ± standardized deviation of the mean, and as proportions (gender). 
Mann-Whitney U test for skewed data; Student t test for normally distributed data; Pearson χ2 test for proportions.




Copyright © 2018 International Anesthesia Research Society. Unauthorized reproduction of this article is prohibited.
       
June 2018 • Volume 126 • Number 6 www.anesthesia-analgesia.org 1953
improvement between 61.1% and 100% was achieved for 
variables in the whole cohort and between 44.3% and 100% 
for variables in subgroup 1. The area under the receiver 
operating characteristic curves for the propensity scores 
was 0.7673 (95% CI, 0.7533–0.7813) for the whole cohort 
and 0.7985 (95% CI, 0.778–0.8191) for subgroup 1, respec-
tively, demonstrating good sensitivity and specificity of 
the propensity scores.
Primary Outcome Parameter
We observed significant differences in the frequency of 
pAKF between study groups. In group RA-HES, the need 
for a postoperative RRT was significantly reduced com-
pared to group RA. The corresponding data, including 
the number of cases, is given in Table 3. The odds ratio for 
patients who had received RA alone compared to those who 
had been given RA and HES 130/0.4 was 1.81, 95% CI, 1.08–
3.04; P = .024. The differences in cumulative frequencies of 
postoperative RRT between groups are demonstrated in 
Supplemental Digital Content 4, Figure 1, http://links.lww.
com/AA/C197.
Secondary Outcome Parameters
In-hospital mortality rates, the frequency of postopera-
tive ICU care, and data concerning LOSH are given in 
Table  3 as well. Here, only 1 relevant difference could 
be noted: Patients belonging to group RA-HES proved 
to have a significantly longer LOSH when compared to 
group RA.
Continuous secondary outcome variables are also dem-
onstrated in Table  3. Patients who received HES 130/0.4 
had slightly (but clinically irrelevant) inferior hemody-
namic conditions (MAP, heart rate), but, on the other 
hand, suffered from a substantially increased blood loss. 
Platelet and fresh frozen plasma requirements were simi-
lar between groups. Patients of group RA-HES needed 
significantly more crystalloids than patients of group RA 
itself. This result was valid when calculating the amount 
of crystalloids per procedure as well for crystalloids given 
throughout anesthesia in milliliter per kilogram body-
weight per hour.
Subgroup 1
Primary and secondary outcome variables for patients who 
underwent major surgery are given in Table 4. In contrast 
to the whole cohort, a significant difference in incidence 
of pAKF was not observed. The odds of developing pAKF 
for patients in group RA were 8% greater than for group 
RA-HES (odds ratio, 1.08, 95% CI, 0.49–2.41; P = .83). In 
terms of secondary outcomes, the intergroup differences are 
largely consistent with those of the whole cohort, including 
mortality rates, frequency of ICU care, LOSH, blood loss, 
consumption of blood products, and crystalloid require-
ments. The (clinically insignificant) differences in hemody-
namic stability seen between groups in the whole cohort 
were not observed in subgroup1.
Subgroup 2
There were 1493 matched patients in whom the RIFLE crite-
ria could be applied. Significant intergroup differences were 
not detected (Table 5).
DISCUSSION
This study investigated adverse effects in patients receiv-
ing HES 130/0.4 combined with RA in comparison to those 
receiving exclusively RA as an intraoperative fluid replace-
ment. A total of 9085 patients were included in the investi-
gation. The administration of HES 130/0.4 did not induce 
an increased frequency of pAKF, nor did it influence mor-
tality rates or the need for ICU care. However, periopera-
tive blood loss in group RA-HES was as twice as high as in 
group RA and the treatment with HES 130/0.4 was associ-
ated with a prolonged LOSH.
Table 2.   Distribution of Surgical Procedures
 All Before 
Matching
Crystalloid 
Versus HES After 
Matching
 RA RA-HES
Cardiac surgery 8.05 13.75 11.72
Endocrinologic surgery 0.94 0.74 0.65
Gynecologic surgery 12.09 5.35 4.52
Neck, nose, and ear surgery 11.20 4.70 0.83
Surgery of lymphatic tissue 1.68 1.85 1.11
Major abdominal surgery 3.65 2.86 4.89
Major neurosurgery 6.25 7.38 6.64
Major trauma surgery 16.13 12.08 17.90
Major urologic surgery 5.13 5.54 3.41
Minor abdominal surgery 9.66 9.23 19.74
Minor neurosurgery 0.72 0.65 0.00
Minor trauma surgery 3.99 3.32 0.55
Minor urologic surgery 6.03 6.83 7.66
Obstetric surgery 4.45 3.23 8.95
Orofacial surgery 0.26 0.46 0.00
Skin surgery 3.57 5.44 2.03
Thoracic and pulmonal surgery 1.45 3.14 3.23
Vascular surgery 4.73 13.47 6.18
All values are given as proportions (%). Pearson χ2 test (P < .001).
Abbreviations: RA, Ringer’s acetate; HES, hydroxyethyl starch 130/0.4.
Table 3.   Primary and Secondary Outcome 
Parameters, Whole Cohort
 
Crystalloid Versus HES After  
Matching (n = 1084/1084)
 RA RA-HES P
Incidence of postoperative 
acute kidney failure 
requiring RRT (%)
3.78 2.12 .022
In-house mortality (%) 2.58 2.68 .492
Need for ICU therapy (%) 30.5 34.3 .062
Length of hospital stay (d) 10.0 (5/17) 12.0 (8/19) <.001
Blood loss (mL/procedure) 406 ± 821 867 ± 1275 <.001
Fresh frozen plasma  
(mL/procedure)
210 ± 632 205 ± 700 .904
Platelets (mL/procedure) 63 ± 218 43 ± 066 .052
RA (mL/procedure) 1801 ± 1099 2270 ± 1115 <.001
RA throughout the duration 
of anesthesia (mL/kg/h)
7.8 ± 4.9 9.6 ± 5.3 .014
HES (mL/procedure) - 500 (500/1000) -
MAP (mm Hg) 81.5 ± 13.2 79.8 ± 10.7 .006
HR (1/min) 67 ± 15 71 ± 17 <.001
Skewed data are given as median (25th/75th percentile), normally distributed 
date as mean ± standardized deviation of the mean, and as proportions. 
Mann-Whitney U test for skewed data; Student t test for normally distributed 
data; Pearson χ2 test for proportions.
Abbreviations: HES, hydroxyethyl starch 130/0.4; HR, heart rate; ICU, 
intensive care unit; MAP, mean arterial pressure; RA, Ringer’s acetate; RRT, 
renal replacement therapy.
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An advantage of the statistical model used in our inves-
tigation is the possibility to generate a large database suffi-
ciently powerful to detect intergroup differences in terms of 
pAKF, which is a rare event in perioperative patients (1%–
7% according to ref. 24). The study population was sub-
jected to a distinct matching process to obtain a far-reaching 
similarity of medically relevant conditions in the study 
groups. In terms of bias control, propensity score match-
ing has been found to be more useful than other statistical 
methods if the treatment groups are highly imbalanced, 
the number of confounders is large, and/or the number of 
events is low.10,25–27 This accurately describes the characteris-
tics of the current investigations and therefore our approach 
should effectively mitigate the disadvantages of unmatched 
retrospective studies, in terms of bias and confounders.25,26
The potential for HES to cause kidney injury was repeat-
edly confirmed by numerous studies in intensive care 
patients.1,2,28 However, only a minority of investigators 
observed an increased incidence of kidney failure in surgi-
cal patients treated with HES. Although 2 large retrospec-
tive investigations associating high-molecular weight HES 
with an impairment of kidney function have been recently 
published, to our knowledge, to date only 1 investigation 
indicates that HES 130/0.4 may also negatively affect the kid-
ney in a perioperative setting.11,29,30 On the contrary, the major-
ity of investigators did not observe associations between 
low-molecular weight HES solutions and kidney injury.5,7,31,32 
The current study confirms the safety of HES 130/0.4 with 
regard to pAKF in a broadly diversified surgical cohort.
Unexpectedly, patients in group RA-HES developed less 
pAKF than patients in group RA. There are only a hand-
ful of previous investigations reporting possible positive 
associations between HES treatment and renal function.33,34 
Jover et al33 observed a positive effect of HES 130/0.40 on 
calculated creatinine clearance. But in this investigation (n = 
29), the mean clearance of the control group was exception-
ally low (61.9 ± 6.6 mL/min), whereas it increased remark-
ably in the HES group (176.4 ± 14.3 mL/min). Thus, the 
relevance of our observations remains unclear especially 
because we found neither significant intergroup differences 
in subgroup 1 (Table 4) nor observed significant periopera-
tive changes of the RIFLE classes (subgroup 2, Table 5). With 
a change rate of the RIFLE classes between 0.8% and 6.8% 
and between 1.3% and 7.2% (P > .05), respectively, the cur-
rent data are consistent with other investigations.35
To date, studies reporting higher mortality rates when 
administering HES preparations exclusively derive from 
the field of ICU care.1,28 Thus, our findings that in-hospital 
mortality rates and the frequency of postoperative ICU care 
are unrelated to HES administration is consistent with the 
literature. In contrast, study results concerning a possible 
influence of modern HES solutions on intraoperative blood 
loss are still conflicting. In 1 meta-analysis and 2 retrospec-
tive trials, an increased blood loss could only be associated 
with high-molecular weight HES preparations, but not with 
HES 130/0.4.6,29,30 However, these results are in contradic-
tion to 2 randomized controlled trials recently published 
by Kancir et al.31,32 In this study, HES therapy was associ-
ated with a blood loss more than twice as high as with RA 
alone. When evaluating this result, several factors must be 
considered. First, blood loss usually depends on the type 
of surgery, which, despite the matching process, was not 
perfectly balanced between groups (Table 2). However, the 
number of patients in cardiac and vascular surgery, usually 
most predisposed to severe blood loss, was higher in group 
RA.36 Second, secondary outcomes in subgroup 1 confirmed 
the increased blood loss in group RA-HES. Summarizing, 
we cannot exclude that intergroup differences in blood loss 
were truly associated with HES 130/0.4 administration and 
not artifacts generated by a study-related bias or confound-
ers. Additionally, our results are in accordance with a meta-
analysis published by Rasmussen.37
Patients in group RA-HES received significantly more 
crystalloids than patients in group RA (Table  3). This can 
be explained by the increased blood loss experienced by 
patients in group RA-HES, which was not fully compen-
sated by the administration of HES and PRBC. This pre-
sumption can be substantiated by some basic calculations 
that are given in Supplemental Digital Content 2, Table 
A2/4 in Appendix 2, http://links.lww.com/AA/C195. 
It becomes evident that the amount of crystalloid given 
closely matches the requirements for isovolemia main-
tenance in both groups.38,39 The adjusted fluid balance for 
Table 4.   Subgroup 1: Primary and Secondary 
Outcome Parameters
 
Crystalloid Versus HES After  
Matching (n = 458/458)
 RA RA-HES P
Incidence of postoperative 
acute kidney failure 
requiring RRT (%)
2.84 2.64 .833
In-house mortality (%) 2.84 4.37 .214
Need for ICU therapy (%) 38.4 35.8 .411
Length of hospital stay (d) 12 (8/19) 14 (9/21) .002
Blood loss (mL/procedure) 425 ± 870 849 ± 1504 <.001
Fresh frozen plasma  
(mL/procedure)
177 ± 599 180 ± 703 .887
Platelets (mL/procedure) 66 ± 257 35 ± 178 .032
RA (mL/procedure) 2179 ± 1239 2304 ± 1120 .031
RA throughout the duration 
of anesthesia (mL/kg/h)
8.8 ± 5.3 9.1 ± 5.1 .024
HES (mL/procedure) - 729 ± 431 -
MAP (mm Hg) 82 ± 11 82 ± 10 .708
HR (1/min) 64 ± 14 66 ± 14 .069
Skewed data are given as median (25th/75th percentile), normally distributed 
data as mean ± standardized deviation of the mean, and as proportions. 
Mann-Whitney U test for skewed data; Student t test for normally distributed 
data; Pearson χ2 test for proportions.
Abbreviations: HES, hydroxyethyl starch 130/0.4; HR, heart rate; ICU, 
intensive care unit; MAP, mean arterial pressure; RA, Ringer’s acetate; RRT, 
renal replacement therapy.
Table 5.   Subgroup 2: RIFLE Criteria in Patients 
With Measured Perioperative Creatinine Values
RIFLE Criteria RA Versus RA-HES P n
No change (%) 88.4 89.6 .81 637/820
Risk (%) 7.2 6.8   
Injury (%) 3.1 2.6   
Failure (%) 1.3 0.8   
Proportions are given in %. Fisher exact test or Pearson χ2 test for proportions, 
respectively. The RIFLE classification was based on serum creatinine values 
only. Urine output criteria were ignored.
Abbreviations: RA, Ringer’s acetate; RIFLE, Risk of renal failure, Injury to the 
kidney, Failure of kidney function, Loss of kidney function, and End-stage renal 
failure; HES, hydroxyethyl starch 130/0.4.
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crystalloids was +101 mL for patients of group RA and +30 
mL for patients of group RA-HES, respectively. Treatment 
with HES 130/0.4 was also associated with a prolonged 
LOSH. The reason for this is unclear. However, one can 
speculate that the increased blood loss in group RA-HES 
may have contributed to this result.
Limitations
In this investigation, we configured the matching proce-
dure as effective as possible. However, there are several 
indicators suggesting that the matching process was good, 
but not perfect. First, the type of surgery, PRBC, and nor-
adrenaline requirements could not be completely balanced 
between groups. Second, LOSH was significantly shorter in 
group RA. We could not discriminate whether participants 
of group RA were less affected by the surgical process or 
whether this effect was caused by greater blood losses in 
group RA-HES. Nevertheless, the matching process was 
highly effective, leading to a variable balance improvement 
up to 100% (Supplemental Digital Content 3, Appendix 3, 
http://links.lww.com/AA/C196).35,40
Defining pAKF as the need for first time RRT may also 
be questionable because the decision when to start RRT 
differs among health care providers. This implicates the 
danger of a personal bias. However, this affected both 
groups equally and should not have influenced intergroup 
comparisons. Though well defined by institutional SOPs 
and controlled by senior anesthetists, the amount of fluid 
administered could not be controlled by the study proto-
col due to the retrospective nature of this investigation. 
This may be regarded as a relevant confounder. However, 
fluid administration was moderate in both study groups 
and largely similar to other investigations.32 Furthermore, 
given this affected both groups equally, it should have had 
little influence on the results of this investigation. Finally, it 
must be stated that we exclusively evaluated HES 130/0.4. 
Therefore, the results of this investigation are not valid for 
other HES preparations currently available.
CONCLUSIONS
In this propensity score matched cohort study, we did 
not find an association between HES 130/0.4 therapy and 
pAKF, when compared to crystalloids alone. HES 130/0.4 
did not negatively influence mortality and the need for ICU 
therapy. However, the use of this colloid was associated 
with an increased blood loss. E
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